論文（2008）

英文原著

• Kuroda J, Matsumoto Y, Tanaka R, Kurita K, Kobayashi T, Shimizu D, Kimura S, Ashihara E, Horiike S, Shimazaki C, Taniwaki M. JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation co-exits, but originate from separate clones. Acta Haematol 120:177-81, 2008.
• Mishima Y, Terui Y, Mishima Y, Taniyama A, Kuniyoshi R, Takizawa T, Kimura S, Ozawa K, Hatake K. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci 99: 2200-2208, 2008.
• Kawata E, Ahihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi Y, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T. Administration of PLK-1 siRNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther 7: 2904-2912, 2008.
• Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, Tanaka H, Yui Y, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Yoshikawa T, Maekawa T, Nakahata T, Adachi S. Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Diff 15: 1712-1722, 2008.
• Kuroda J, Kamitsuji M, Kimura S, Ashihara E, Nakagawa Y, Kawata E, Takeuchi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T. Anti-myeloma effect of Homoharringtonine with concomitant targeting of multiple myeloma-promoting molecules, Mcl-1, XIAP and b-catenin. Int J Hematol 87: 507-515, 2008.
• Muramatsu H, Kimura S, Ichinohe T, Ashihara E, Ishikawa T, Maekawa T, Uchiyama T. Consulting clinic for related family donors in hematopoietic stem cell transplantation. Bone Marrow Transplant 41: 1073-1075. 2008.
• Shimura K, Ahihara E, Shimazaki C, Matsunaga S, Taniguchi K, Uchiyama H, Matsumoto Y, Kimura S, Matsubara H, Taniwaki M, Maekawa T. Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease. Biol Blood Marrow Tr 14: 426-437, 2008.
• Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata E, Takeuchi M, Murotani Y, Yokota A, Hirai M, Majima S, Taniwaki M, Maekawa T, Kimura S. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res, 32: 1462-1467, 2008.
• Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib induces CML cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7: 48-58, 2008.
• Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib, and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer 122: 2621-2627, 2008.
• Kuroda J, Kimura S, Andreef M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. ABT-737 is a useful component of combinatory chemotherapies for chronic myelogenous leukaemias with diverse drug resistance mechanisms. Brit J Haematol 140: 181-190, 2008.
• Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980-983, 2008.
• Sato A, Sueoka-Aragane N, Saitoh J, Komiya K, Hisatomi T, Tomimasu R, Hayashi S, Sueoka E. Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma hnRNP B1 mRNA, a biomarker of lung canxer. J Cancer Res Clin Oncol 134: 1191-1197, 2008.
• Sueoka-Aragane N, Imai K, Komiya K, Sato A, Tominasu R, Hisatomi T, Sakuragi T, Mitsuoka M, Hayashi S, Nakachi K, Sueoka E. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci 99: 1080-1087, 2008.
• Yukitake M, Sueoka E, Sueoka-Aragane N, Sato A, Ohashi H, Yakushiji Y, Saito M, Osame M, Izumo S, Kuroda Y. Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 14: 130-135, 2008.
• Kobayashi H, Sano A, Aragane N, Fukuoka M, Tanaka M, Kawaura F, Fukuno Y, Matsuishi E, Hayashi S. Disseminated infection by Bipolaris spicifera in an immunocompetent subject. Med Mycol 46:361-365, 2008.
• Hayashi S, Tanaka M, Kobayashi H, Nakazono T, Satoh T, Fukuno Y, Aragane N, Tada Y, Koarada S, Ohta A, Nagasawa K. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 35:260-269, 2008.

英文総説

• Yokota A, Kimura S. Novel Agents to Override Imatinib Resistance Mechanisms. Drug Development Research, 69: 398-406, 2008.
• Tanaka R, Kimura S. From the second generation Abl tyrosine kinase inhibitors to the next generation for overriding Bcr-Abl/T315I. Expert Review of Anticancer Ther 8: 1387-1398, 2008.

邦文原著

• 田中彩、荒金尚子、小宮一利、川浦太、福野裕次、林真一郎. 既治療非小細胞肺癌に対するCPT-11とCDDP併用療法のPilot Study. 癌と化学療法 35:1, 2008.
• 小林弘美、琴岡憲彦、田尾朋子、川浦太、田中将英、福野裕次、荒金尚子、中原快明、林真一郎. 近位気管支狭窄および著明な右室の拡大を伴ったサルコイドーシスの一例. 日本呼吸器学会雑誌. 46:1, 2008

邦文著書

• 木村晋也. あらたなABLチロシンキナーゼ阻害剤. 医学のあゆみ.（戸井雅和編集）、医歯薬出版、東京、p103-108, 2008
• 前川　平、芦原英司、木村晋也. シグナル伝達系阻害剤．がんの分子標的治療 （鶴尾 隆 編集）、南山堂、東京、p291-298, 2008.
• 木村晋也、黒田純也. ゾレドロン酸によるRas関連蛋白を分子標的とした造血悪性腫瘍治療の可能性. 医学のあゆみ.（黒川峰夫編集）、医歯薬出版、東京、p113-118, 2008.

邦文総説

• 木村晋也. 小動物におけるin vivoイメージング技術の進歩. 試薬会誌 26; 19-21, 2008.
• 木村晋也. ビスホスホネートでex vivo 増幅したγδT細胞による免疫細胞療法. Clinical Calcium 18; 81-87, 2008.
• 木村晋也. あらたなABLチロシンキナーゼ阻害剤　イマチニブ耐性克服を目指して. 医学のあゆみ 224:109-114, 2008.
• 木村晋也. 新規ABLチロシンキナーゼ阻害剤－生き残るのはどれか－. ファルマシア 44: 213-217, 2008.
• 木村晋也. （文献紹介）RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. 分子細胞治療 7; 90-91, 2008.

最終更新日：2014年10月1日